FRI0159 Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from An Ontario Rheumatoid Arthritis Cohort

Background Clinical evidence suggests concomitant treatment with a biologic Disease-Modifying Antirheumatic Drug (bDMARD) and a conventional synthetic DMARD (csDMARD), especially with methotrexate (MTX), has greater efficacy than treatment with a bDMARD as monotheapy in patients with rheumatoid arthritis (RA). However, not all patients are able to tolerate a csDMARD. Objectives Our objective was to compare the persistence of a bDMARD used as …